Adlai Nortye adds MD Anderson’s David Hong, MSK’s Piro Lito to scientific advisory board
ANL•Appointments support RAS inhibitor pipeline
The additions support clinical development priorities for the group’s RAS inhibitor pipeline, including AN9025 and AN4035, alongside immuno-oncology candidate AN8025.
Scientific advisory board expands with two oncology specialists
Adlai Nortye expanded its Scientific Advisory Board with the appointments of medical oncologists David S. Hong and Piro Lito.
Hong serves as Deputy Chair in Investigational Cancer Therapeutics at UT MD Anderson Cancer Center, focused on translational and early-stage clinical development.
Lito is Director of Basic and Translational Research in Solid Tumor Oncology at Memorial Sloan Kettering, known for research underpinning KRAS G12C inhibitor development.
